RecruitingRecruiting
A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
NCT07881887 · Eli Lilly and Company
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
About this study
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Eligibility criteria
Inclusion Criteria:
* Participants must be 21 in Singapore.
* Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change.
Part A, B, D, and E
* Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:
* hypertension
* dyslipidemia
* obstructive sleep apnea, or
* prediabetes.
Part C
* Have a BMI ≥25.0 kg/m²
* Have a diagnosis of Type 2 Diabetes (T2D) for at least 6 months.
* T2D controlled with diet and exercise alone or are on a stable dose of metformin alone, or in combination with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i), for at least 3 months.
* Have a hemoglobin (HbA1c) value of ≥6.5 % and ≤10.0%.
Part D
* To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 of the participants' biological grandparents being of exclusive Chinese descent and born in China.
Part E
* To qualify as Japanese for this study, the participant must be at a minimum third-generation Japanese, defined as having all 4 of the participants' biological grandparents being of exclusive Japanese descent and born in Japan.
Exclusion Criteria:
* Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
Study design
Enrollment target: 617 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2026-10-22
Estimated completion: 2029-03
Last updated: 2026-11-18
Interventions
Drug: LY4167586Drug: Placebo
Primary outcomes
- • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (Baseline through Study Completion (Estimated as Week 89))
Sponsor
Eli Lilly and Company · industry
Contacts & investigators
ContactTrial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · contact · LillyTrials@Lilly.com · 1-317-615-4559
ContactPhysicians interested in becoming principal investigators please contact · contact · clinical_inquiry_hub@lilly.com
InvestigatorCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · study_director, Eli Lilly and Company
All locations (15)
Woodland Research Northwest, LLCNot Yet Recruiting
Rogers, Arkansas, United States
CenExel ACTRecruiting
Anaheim, California, United States
Collaborative Neuroscience Network - CNSRecruiting
Los Alamitos, California, United States
Diablo Clinical Research, Inc.Recruiting
Walnut Creek, California, United States
Fortrea Clinical Research UnitRecruiting
Daytona Beach, Florida, United States
Advanced Pharma CR, LLCNot Yet Recruiting
Miami, Florida, United States
Clinical Site Partners, LLC DBA CSP OrlandoRecruiting
Winter Park, Florida, United States
Centricity ResearchRecruiting
Columbus, Georgia, United States
CenExel iResearch, LLCRecruiting
Decatur, Georgia, United States
QPSRecruiting
Springfield, Missouri, United States
CenExel-HRIRecruiting
Marlton, New Jersey, United States
Ohio Clinical TrialsRecruiting
Columbus, Ohio, United States
Fortrea Clinical Research UnitRecruiting
Dallas, Texas, United States
Worldwide Clinical Trials, Inc.Recruiting
San Antonio, Texas, United States
Lilly Centre for Clinical PharmacologyNot Yet Recruiting
Singapore, Singapore